SciSparc Ltd.（SPRC）旗下子公司 Neurothera Labs 宣布，已启动一项针对抽动秽语综合征（Tourette Syndrome）创新疗法的 IIb 期临床试验。该试验将在德国汉诺威医学院（Hannover Medical School）进行。
此次临床研究的启动标志着该公司针对这一神经系统疾病的核心候选疗法进入了新的关键阶段。试验旨在评估该创新疗法的安全性与有效性，为后续的临床开发提供重要数据支持。
抽动秽语综合征是一种复杂的神经发育障碍，患者常出现不自主的抽动和发声。目前该领域的治疗选择有限，存在显著的未满足医疗需求。Neurothera Labs 的研发项目旨在探索新的治疗途径。
汉诺威医学院作为欧洲领先的医学研究中心之一，将为此次临床试验提供专业的科研环境和临床资源。此次合作有助于加速疗法的开发进程，并可能为全球患者带来新的希望。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.